Fig. 2

BCMA-CD38 CAR-T cells had potent activity against intramedullary lesion in MM patients. A The duration of response to BCMA-CD38 CAR-T in 16 cases was assessed according to IMWG 2016. B The best objective response (BOR) after BCMA-CD38 CAR-T infusion to the cut off data. C The PFS curves of patients after BCMA-CD38 CAR-T infusion. D The OS curves of patients after BCMA-CD38 CAR-T infusion. E Left: CD38 expression by FCM in bone marrow before and 1 month after CAR-T cell infusion was compared. Right: Serum MIg determined by SPEP before and 1 month after CAR-T cell infusion was compared. Wilcoxon matched-pairs signed rank test was used for statistical comparison. F Left: The amplification curves of CAR+ T cells in peripheral blood of patients (response ≥VGPR) assessed by FCM; Middle: The amplification curves of CAR+ T cells in peripheral blood of patients (response <VGPR) assessed by FCM; Right: Peak values of CAR+ T cells in peripheral blood of patients assessed by FCM were compared between patients whose response ≥VGPR and response <VGPR after CAR-T delivery